Rob Stein | Texas Public Radio

Rob Stein

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.

Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

Americans continue to wait in long lines to get tested for the coronavirus. Many then face frustration and anxiety waiting days — sometimes even weeks — to get their results.

Could technology finally solve the testing woes that have hobbled the nation's ability to fight the pandemic? The National Institutes of Health hopes so.

When the coronavirus pandemic began, public health experts had high hopes for the United States. After all, the U.S. literally invented the tactics that have been used for decades to quash outbreaks around the world: Quickly identify everyone who gets infected. Track down everyone exposed to the virus. Test everyone. Isolate the sick and quarantine the exposed to stop the virus from spreading.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

The coronavirus keeps spreading around the United States. New hot spots are emerging and heating up by the day. The death toll keeps mounting. So how can the U.S. beat back the relentless onslaught of this deadly virus?

Public health experts agree on one powerful weapon that's gotten a lot of attention but apparently still needs a lot more: testing.

A new analysis that researchers at Harvard conducted for NPR finds that more states have begun to do enough testing to keep their outbreaks from getting worse, but most are still falling short.

Like millions of other Americans, Victoria Gray has been sheltering at home with her children as the U.S. struggles through a deadly pandemic, and as protests over police violence have erupted across the country.

But Gray is not like any other American. She's the first person with a genetic disorder to get treated in the United States with the revolutionary gene-editing technique called CRISPR.

All laboratories will now be required to include detailed demographic data when they report the results of coronavirus tests to the federal government, including the age, sex, race and ethnicity of the person tested, the Trump administration announced Thursday.

The new requirement, which will go into effect Aug. 1, is designed to help provide long-sought, crucial information needed to monitor and fight the pandemic nationally.

The head of the federal Centers for Disease Control and Prevention said Friday that a new analysis shows the agency's delayed rollout of coronavirus testing did not hinder the nation's response to the pandemic.

The coronavirus didn't start spreading in the U.S. until late January or early February, the CDC analysis found, and it circulated at low levels for quite some time.

As a result, the availability of earlier widespread testing for the virus would not have been able to spot it, according to CDC Director Robert Redfield.

Salvador Perez got really sick in April. He's 53 and spent weeks isolated in his room in his family's Chicago apartment, suffering through burning fevers, shivering chills, intense chest pain and other symptoms of COVID-19.

"This has been one of the worst experiences of his life," says Perez's daughter, Sheila, who translated from Spanish to English for an interview with NPR. "He didn't think he was going to make it."

Copyright 2020 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

Pages